ImmunityBio
IBRX
IBRX
63 hedge funds and large institutions have $56.1M invested in ImmunityBio in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
3.41% less ownership
Funds ownership: 19.11% → 15.71% (-3.4%)
33% less capital invested
Capital invested by funds: $83.2M → $56.1M (-$27.1M)
95% less call options, than puts
Call options by funds: $4K | Put options by funds: $80K
Holders
63
Holding in Top 10
1
Calls
$4K
Puts
$80K
Top Buyers
| 1 | +$1.09M | |
| 2 | +$364K | |
| 3 | +$338K | |
| 4 |
Morgan Stanley
New York
|
+$209K |
| 5 |
Renaissance Technologies
New York
|
+$197K |
Top Sellers
| 1 | -$11.6M | |
| 2 | -$1.63M | |
| 3 | -$561K | |
| 4 |
BlackRock
New York
|
-$399K |
| 5 |
SG Americas Securities
New York
|
-$270K |